Cargando…

The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

BACKGROUND: Although being considered as a rarely observed HIV-1 protease mutation in clinical isolates, the L76V-prevalence increased 1998-2008 in some European countries most likely due to the approval of Lopinavir, Amprenavir and Darunavir which can select L76V. Beside an enhancement of resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiesmann, Frank, Vachta, Jan, Ehret, Robert, Walter, Hauke, Kaiser, Rolf, Stürmer, Martin, Tappe, André, Däumer, Martin, Berg, Thomas, Naeth, Gudrun, Braun, Patrick, Knechten, Heribert
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049128/
https://www.ncbi.nlm.nih.gov/pubmed/21314993
http://dx.doi.org/10.1186/1742-6405-8-7
_version_ 1782199207612907520
author Wiesmann, Frank
Vachta, Jan
Ehret, Robert
Walter, Hauke
Kaiser, Rolf
Stürmer, Martin
Tappe, André
Däumer, Martin
Berg, Thomas
Naeth, Gudrun
Braun, Patrick
Knechten, Heribert
author_facet Wiesmann, Frank
Vachta, Jan
Ehret, Robert
Walter, Hauke
Kaiser, Rolf
Stürmer, Martin
Tappe, André
Däumer, Martin
Berg, Thomas
Naeth, Gudrun
Braun, Patrick
Knechten, Heribert
author_sort Wiesmann, Frank
collection PubMed
description BACKGROUND: Although being considered as a rarely observed HIV-1 protease mutation in clinical isolates, the L76V-prevalence increased 1998-2008 in some European countries most likely due to the approval of Lopinavir, Amprenavir and Darunavir which can select L76V. Beside an enhancement of resistance, L76V is also discussed to confer hypersusceptibility to the drugs Atazanavir and Saquinavir which might enable new treatment strategies by trying to take advantage of particular mutations. RESULTS: Based on a cohort of 47 L76V-positive patients, we examined if there might exist a clinical advantage for L76V-positive patients concerning long-term success of PI-containing regimens in patients with limited therapy options. Genotypic- and phenotypic HIV-resistance tests from 47 mostly multi-resistant, L76V-positive patients throughout Germany were accomplished retrospectively 1999-2009. Five genotype-based drug-susceptibility predictions received from online interpretation-tools for Atazanavir, Saquinavir, Amprenavir and Lopinavir, were compared to phenotype-based predictions that were determined by using a recombinant virus assay along with a Virtual Phenotype™(Virco). The clinical outcome of the L76V-adapted follow-up therapy was determined by monitoring viral load for 96 weeks. CONCLUSIONS: In this analysis, the mostly used interpretation systems overestimated the L76V-mutation concerning Atazanavir- and SQV resistance. In fact, a clear benefit in drug susceptibility for these drugs was observed in phenotype analysis after establishment of L76V. More importantly, long-term therapy success was significantly higher in patients receiving Atazanavir and/or Saquinavir plus one L76V-selecting drug compared to patients without L76V-selecting agents (p = 0.002). In case of L76V-occurrence ATV and/or SQV may represent encouraging options for patients in deep salvage situations.
format Text
id pubmed-3049128
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30491282011-03-06 The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage? Wiesmann, Frank Vachta, Jan Ehret, Robert Walter, Hauke Kaiser, Rolf Stürmer, Martin Tappe, André Däumer, Martin Berg, Thomas Naeth, Gudrun Braun, Patrick Knechten, Heribert AIDS Res Ther Short Report BACKGROUND: Although being considered as a rarely observed HIV-1 protease mutation in clinical isolates, the L76V-prevalence increased 1998-2008 in some European countries most likely due to the approval of Lopinavir, Amprenavir and Darunavir which can select L76V. Beside an enhancement of resistance, L76V is also discussed to confer hypersusceptibility to the drugs Atazanavir and Saquinavir which might enable new treatment strategies by trying to take advantage of particular mutations. RESULTS: Based on a cohort of 47 L76V-positive patients, we examined if there might exist a clinical advantage for L76V-positive patients concerning long-term success of PI-containing regimens in patients with limited therapy options. Genotypic- and phenotypic HIV-resistance tests from 47 mostly multi-resistant, L76V-positive patients throughout Germany were accomplished retrospectively 1999-2009. Five genotype-based drug-susceptibility predictions received from online interpretation-tools for Atazanavir, Saquinavir, Amprenavir and Lopinavir, were compared to phenotype-based predictions that were determined by using a recombinant virus assay along with a Virtual Phenotype™(Virco). The clinical outcome of the L76V-adapted follow-up therapy was determined by monitoring viral load for 96 weeks. CONCLUSIONS: In this analysis, the mostly used interpretation systems overestimated the L76V-mutation concerning Atazanavir- and SQV resistance. In fact, a clear benefit in drug susceptibility for these drugs was observed in phenotype analysis after establishment of L76V. More importantly, long-term therapy success was significantly higher in patients receiving Atazanavir and/or Saquinavir plus one L76V-selecting drug compared to patients without L76V-selecting agents (p = 0.002). In case of L76V-occurrence ATV and/or SQV may represent encouraging options for patients in deep salvage situations. BioMed Central 2011-02-13 /pmc/articles/PMC3049128/ /pubmed/21314993 http://dx.doi.org/10.1186/1742-6405-8-7 Text en Copyright ©2011 Wiesmann et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Report
Wiesmann, Frank
Vachta, Jan
Ehret, Robert
Walter, Hauke
Kaiser, Rolf
Stürmer, Martin
Tappe, André
Däumer, Martin
Berg, Thomas
Naeth, Gudrun
Braun, Patrick
Knechten, Heribert
The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
title The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
title_full The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
title_fullStr The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
title_full_unstemmed The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
title_short The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
title_sort l76v mutation in hiv-1 protease is potentially associated with hypersusceptibility to protease inhibitors atazanavir and saquinavir: is there a clinical advantage?
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049128/
https://www.ncbi.nlm.nih.gov/pubmed/21314993
http://dx.doi.org/10.1186/1742-6405-8-7
work_keys_str_mv AT wiesmannfrank thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT vachtajan thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT ehretrobert thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT walterhauke thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT kaiserrolf thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT sturmermartin thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT tappeandre thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT daumermartin thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT bergthomas thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT naethgudrun thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT braunpatrick thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT knechtenheribert thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT wiesmannfrank l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT vachtajan l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT ehretrobert l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT walterhauke l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT kaiserrolf l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT sturmermartin l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT tappeandre l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT daumermartin l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT bergthomas l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT naethgudrun l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT braunpatrick l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage
AT knechtenheribert l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage